STOCK TITAN

Lilly Eli & Co - LLY STOCK NEWS

Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.

Overview

Lilly Eli & Co (LLY) is a globally recognized pharmaceutical powerhouse with a heritage that spans nearly a century and a half. Founded in 1876 by Colonel Eli Lilly, the company has consistently transformed scientific research into life‐changing therapies while establishing itself as an authority in pharmaceutical innovation. Operating from its headquarters in Indianapolis, Indiana, Lilly Eli & Co has built a network that spans multiple continents and markets, embodying a commitment to advanced research and manufacturing excellence.

Business Model and Core Competencies

The company generates revenue primarily through the development, production, and global distribution of therapeutic medicines. Its diverse portfolio is underpinned by breakthrough R&D in biotechnology and chemical synthesis. By leveraging strategic investments in research, the company has developed innovative treatments for critical areas such as diabetes, oncology, immunology, and neuroscience. These initiatives not only address significant unmet medical needs but also strengthen its competitive edge in the highly dynamic pharmaceutical sector.

Innovative Research and Development

Lilly Eli & Co excels in turning cutting-edge scientific discoveries into practical, market-ready solutions. The company’s approach integrates state-of-the-art biotechnology, chemical innovation, and genetic medicine – elements that drive its robust R&D engine and pave the way for advances in areas such as targeted cancer therapies, metabolic management, and chronic disease care. Its research programs emphasize both precision medicine and large-scale production, ensuring that new therapies are both effective and accessible.

Global Manufacturing and Supply Chain Excellence

In addition to its research prowess, Lilly Eli & Co has a well-established global manufacturing network. The company has continually expanded its facilities, investing in advanced production capabilities to maintain a reliable supply chain. This commitment to manufacturing excellence helps ensure that high-quality products are delivered efficiently to patients worldwide, reinforcing its reputation as a dependable partner in healthcare.

Market Position and Competitive Edge

As an integrated leader in pharmaceutical technology and therapeutics, Lilly Eli & Co has positioned itself at the intersection of innovation and reliability. The company competes through a blend of long-term research investments, strategic global partnerships, and a relentless focus on improving patient outcomes. Its strong brand legacy and comprehensive portfolio of drugs underline a commitment to scientific excellence and unwavering operational execution.

Commitment to Quality and Patient-Centric Solutions

Quality and trust are central to the company's ethos. With a history of rigorous clinical trials and regulatory approvals, Lilly Eli & Co ensures that its medicines meet the highest standards of safety and efficacy. This patient-centric approach, combined with sustainable manufacturing practices, makes it a reliable source of advanced therapies, fostering long-term trust among healthcare providers and patients alike.

Industry Keywords and Expertise

Industry-specific terms such as pharmaceutical innovation, biotechnology, therapeutics, and advanced manufacturing are integral to understanding the company’s operations. These terms reflect the scientific depth and operational expertise that have allowed Lilly Eli & Co to remain at the forefront of drug discovery and development.

Conclusion

With its rich history, expansive R&D capabilities, and global operational reach, Lilly Eli & Co is a testament to the power of innovation in healthcare. This comprehensive overview highlights not only its diversified business model and advanced research but also its enduring commitment to enhancing patient lives through high-quality, accessible, and effective medicines.

Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced positive Phase 2 results for lepodisiran, an investigational siRNA therapy targeting lipoprotein(a) [Lp(a)]. The ALPACA study demonstrated that lepodisiran reduced Lp(a) levels by 93.9% at the highest tested dose (400 mg) over 60-180 days, meeting its primary endpoint.

Key findings include:

  • 16 mg dose achieved 40.8% reduction
  • 96 mg dose achieved 75.2% reduction
  • 400 mg dose maintained 91% reduction at 1 year
  • 74.2% reduction persisted at 1.5 years

The treatment showed a favorable safety profile with minimal adverse events. About 20% of Americans have high Lp(a) levels, which can double or triple heart attack risk. The company is currently conducting the ACCLAIM-Lp(a) Phase 3 trial to evaluate cardiovascular outcomes in adults with elevated Lp(a).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Eli Lilly (LLY) has expanded its LillyDirect digital healthcare platform to improve access to Alzheimer's disease care in the U.S. through independent in-person and telehealth options. The expansion aims to address significant healthcare challenges, as the majority of the nearly 7 million Americans with Alzheimer's remain undiagnosed.

The platform now includes Healthgrades, a doctor locator tool for finding local clinicians experienced in Alzheimer's care, and Synapticure, an independent telehealth provider specializing in neurodegenerative care. Synapticure commits to connecting patients with care navigators within two days and neurologist appointments within two weeks.

This initiative addresses critical issues in Alzheimer's care, including:

  • Wait times expected to exceed 1 year by 2025
  • Nearly 1 in 5 Medicare beneficiaries traveling over 50 miles to see neurologists
  • Approximately 3,000 Americans progressing daily from mild to moderate/severe stages

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
-
Rhea-AI Summary

Eli Lilly (NYSE: LLY) has announced upcoming presentations of preclinical data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30. The company will showcase two key developments:

1. LY4050784: A selective SMARCA2 inhibitor, developed in collaboration with Foghorn Therapeutics, showing synergistic activity when combined with chemotherapy, pembrolizumab, and KRAS inhibitors in SMARCA4 mutant cancers.

2. LY4066434: A pan-KRAS inhibitor demonstrating high selectivity over HRAS and NRAS, with robust anti-tumor activity in KRAS-mutant models, including in the CNS.

Both programs are currently in Phase 1 clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
none
Rhea-AI Summary

Eli Lilly (NYSE: LLY) reported promising Phase 3 BRAVE-AA-PEDS study results for baricitinib in treating adolescents with severe alopecia areata (AA). The study involved 257 patients aged 12-18 years.

Key findings at Week 36 showed that 42.4% of patients receiving 4mg baricitinib achieved 80% or more scalp hair coverage, compared to 4.5% on placebo. The 4mg dose group also demonstrated significant improvements with 50% achieving eyebrow regrowth and 42.9% showing eyelash regrowth.

Results suggest faster hair regrowth in adolescents compared to adults, with comparable efficacy achieved at 36 weeks versus 52 weeks in adult studies. The most common side effects included acne, influenza, and upper respiratory tract infection, with no major adverse events reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Eli Lilly's EBGLYSS® (lebrikizumab-lbkz) demonstrated significant long-term efficacy in treating moderate-to-severe atopic dermatitis, according to new three-year data presented at the American Academy of Dermatology Annual Meeting.

Key findings from the ADjoin extension study show that among Week 16 responders receiving monthly maintenance doses:

  • 50% achieved complete skin clearance (EASI 100 or IGA 0)
  • 87% achieved almost-clear skin (EASI 90)
  • 83% did not require additional topical therapies

Additional studies revealed EBGLYSS's effectiveness across diverse patient groups: The ADmirable study showed ~60% of patients with skin of color experienced significant improvement in itch and skin pain at Week 16. In the ADapt study of previous dupilumab users, 75% achieved significant skin pain improvement and 62% showed itch improvement at Week 24.

EBGLYSS, approved in September 2024 as a first-line monotherapy biologic treatment, works by selectively blocking IL-13 signaling. The safety profile remained consistent with previous studies, with mild to moderate adverse effects primarily including conjunctivitis and injection-site reactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
none
-
Rhea-AI Summary

Laekna (2105.HK) has received FDA IND approval for LAE120, a novel USP1 inhibitor for treating advanced solid tumors. LAE120 is characterized as an allosteric and highly potent inhibitor showing strong tumor inhibitory activity across various xenograft models and demonstrating synergistic effects with PARP inhibitors.

The company is also advancing LAE118, a mutant-selective PI3Kα inhibitor currently in IND-enabling studies, with IND filing expected in Q4 2025. LAE118 shows promise as a potential best-in-class treatment for various cancers including breast, colorectal, lung, and endometrial cancers.

Additionally, Laekna has established a clinical collaboration with Lilly (LLY) in November 2024 to accelerate the global clinical development of LAE102 for obesity treatment. The company is actively seeking strategic partnerships to expedite clinical development and commercialization of its drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
Rhea-AI Summary

Eli Lilly (NYSE: LLY) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference scheduled for March 10, 2025. The company's executive vice president and CFO, Lucas Montarce, will engage in a fireside chat at 9:20 a.m. Eastern time.

Investors and interested parties can access a live audio webcast of the presentation through Lilly's investor website in the 'Webcasts & Presentations' section. The recording will remain available for approximately 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
-
Rhea-AI Summary

Eli Lilly's (LLY) Jaypirca (pirtobrutinib) received a positive recommendation from EMA's CHMP for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who were previously treated with a BTK inhibitor.

The recommendation is based on the Phase 3 BRUIN CLL-321 trial results, which demonstrated that Jaypirca reduced disease progression or death risk by 46% compared to standard treatments (median PFS: 14.0 vs. 8.7 months). The median time to next treatment improved by 63% (24 months vs. 11 months).

The trial showed consistent results across key subgroups, including patients with poor prognosis factors. Common adverse reactions included neutropenia, fatigue, diarrhea, anemia, rash, and contusion. The European Commission's final decision is expected within 1-2 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
-
Rhea-AI Summary

Eli Lilly (NYSE: LLY) has announced plans to build four new pharmaceutical manufacturing sites in the United States, bringing its total U.S. capital expansion commitments to over $50 billion since 2020. Three sites will focus on active pharmaceutical ingredients (API) manufacturing and chemical synthesis, while the fourth will expand injectable therapy production.

The expansion will create 3,000 high-skilled jobs including engineers, scientists, and technicians, plus approximately 10,000 construction jobs. The new facilities will manufacture medicines across therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience.

This investment builds upon Lilly's previous domestic expansion commitments of $23 billion from 2020-2024, which included facilities in North Carolina, Indiana, and Wisconsin. The company is currently negotiating with several states and welcomes additional interest by March 12, 2025. Production at the new facilities is expected to begin within five years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) has announced the launch of new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials for $499 per month through the new Zepbound Self Pay Journey Program. The company has also reduced prices of existing 2.5 mg vials to $349 and 5 mg vials to $499 per month.

These offerings are available exclusively through LillyDirect Self Pay Pharmacy Solutions, which provides transparent pricing by eliminating third-party supply chain entities and allowing patients to access savings directly outside of insurance.

The Zepbound Self Pay Journey Program reduces the regular prices of 7.5 mg ($599) and 10 mg ($699) doses to $499 per month at first fill and refills occurring within 45 days of prior delivery.

Zepbound is also available in various dosages in single-dose pen autoinjectors, with recommended maintenance dosages of 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none

FAQ

What is the current stock price of Lilly Eli & Co (LLY)?

The current stock price of Lilly Eli & Co (LLY) is $825.91 as of March 31, 2025.

What is the market cap of Lilly Eli & Co (LLY)?

The market cap of Lilly Eli & Co (LLY) is approximately 724.6B.

What is the primary focus of Lilly Eli & Co?

Lilly Eli & Co is focused on developing, manufacturing, and globally distributing innovative therapeutic medicines across areas like diabetes, oncology, immunology, and neuroscience.

How does the company generate its revenue?

The company generates revenue through its extensive R&D efforts, production of high-quality medicines, and worldwide sales, supported by a robust manufacturing network and strategic global partnerships.

What sets Lilly Eli & Co apart in the pharmaceutical industry?

Its long history of innovation, combined with cutting-edge research, advanced manufacturing capabilities, and a strong commitment to quality, positions Lilly Eli & Co as a trusted and pioneering leader in healthcare.

How does Lilly Eli & Co ensure the quality and safety of its products?

The company follows rigorous clinical trial protocols and regulatory standards, ensuring that every product meets the highest levels of safety and efficacy before reaching patients around the world.

Where is Lilly Eli & Co headquartered?

Lilly Eli & Co is headquartered in Indianapolis, Indiana, and operates an extensive global network to support its manufacturing and research activities.

What role does research and development play at Lilly Eli & Co?

R&D is central to the company’s business model, driving innovation in drug discovery, advanced biotechnology applications, and the development of novel therapies to address critical health challenges.

How does Lilly Eli & Co contribute to global healthcare?

By providing innovative, high-quality medicines across diverse therapeutic areas and maintaining an efficient global distribution network, the company helps improve patient outcomes and supports health systems worldwide.

What are some key industry keywords associated with the company?

Key terms include pharmaceutical innovation, biotechnology, therapeutics, research and development, advanced manufacturing, and clinical excellence.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

724.60B
945.87M
0.17%
83.56%
0.81%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS